What you’re going to do is assemble pieces of artificial DNA according to a certain code to generate protein spikes. The DNA is then delivered into the body as a vaccine.
You can see the works of others who have developed the DNA Vaccine.
Dozens of institutions are already interested in developing vaccines using this brand new method. A company called Genexine has moved to phase I clinical trial at the end of June 2020.
You can decide on DNA Vaccine or consider different options.
It turns out that Kalbe Farma is exploring the possibility of a partnership with Genexine to develop this type of vaccine. You can choose to cooperate with Genexine. Or, if you’re confident enough, try to make your own.
Whoops, we haven’t secured a partnership with Inovio.
You can attempt to initiate collaboration or if you think it takes too much time, consider a different strategy. Your other option is to cooperate with Genexine.
Good choice. Genexine is already cooperating with Kalbe Farma, but by the end of June 2020, their vaccine candidate was still in a pre-clinical stage.
If you’re sure about this, you can continue collaborating with Genexine.
DNA Vaccine is a new thing, which means the finished vaccine will be accompanied by a patent. There will be a price to pay. If you decide to collaborate, you have to think carefully about how it will be carried out. You need to start lobbying early on.
Thinking it’s not the best solution? Let’s go take a look at the other strategies
You will have to wait for Genexine’s vaccine candidate to be ready for clinical trial. Then, you will probably test the vaccine candidate on Indonesians to evaluate its effectiveness. This may become a viable choice.
But what about the long term plan? You can plan to develop your own vaccine or be content with importing it.
DNA-based vaccine requires the latest technologies in its research and production, can you really do this? This is not a good choice for a quick vaccine solution. You can continue working with Genexine.
